← Back to catalogue
Research draft

mpox

vr.tr.mpox · thing-q382370

Enable an AI agent to recognise a possible mpox episode, assess its clinical and transmission state, and identify evidence-supported next actions for authorised clinical or public-health review.

Thing Registry Cross-cutting context XCT.QLT

Research draft, second pass

A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.

Researched by: Codex + Grok

Bundle → Layer → Finding → Questions Filled

6 bundles · 11 layers · 18 findings · 31 questions

Mpox recognition Establish what supports calling an episode mpox and what remains unresolved.

Case definition and differentials

Relate the observed presentation to a versioned case definition and competing explanations.

Supported case classification

Record the classification, its supporting observations and unresolved alternatives separately.

  1. Which jurisdiction's dated mpox case definition applies, and which criteria are satisfied, absent or unknown? definition
  2. How were varicella, herpes, syphilis and other plausible explanations assessed, including possible coinfection? boundary

Laboratory attribution

Preserve what testing establishes about MPXV and what requires additional evidence.

Interpretable mpox test evidence

Link each interpretation to the actual assay, specimen and report rather than a standalone positive or negative label.

  1. What specimen site, collection date, assay target and laboratory report support the result? provenance
  2. Does the assay establish MPXV, broader orthopoxvirus detection or clade attribution, and what limitations qualify a negative or indeterminate result? boundary
  3. What unresolved discrepancy warrants clinician or laboratory review for additional testing? action
Lesions and disease course Represent the anatomical and temporal course of a suspected or confirmed episode.

Cutaneous and mucosal involvement

Capture observed lesions and symptoms at visible and less accessible sites.

Lesion and function profile

Record site-specific findings and distinguish unexamined areas from documented absence.

  1. Which skin, oral, genital, anal or ocular sites are involved, and which were not assessed? measurement
  2. What lesion evolution, pain and interference with eating, drinking, urination or defecation were recorded at each assessment? measurement

Episode progression

Track onset, progression and recovery with uncertainty in dates preserved.

Dated clinical trajectory

Keep symptom onset, lesion onset, new lesion formation and healing as distinct observations.

  1. When did systemic symptoms and lesions first appear, and which dates are recalled estimates? provenance
  2. Does serial assessment show improvement, new lesions, persistent disease or deterioration, and what evidence supports that judgement? measurement
Severity and host context Assess observed clinical burden alongside factors that can alter the course of mpox.

Host vulnerability

Link relevant host conditions and prior protection to the episode assessment.

Individual risk modifiers

Use documented clinical context rather than group membership to qualify risk.

  1. What current evidence describes immune function, pregnancy, age-related considerations and relevant skin disease? provenance
  2. Which previous mpox episodes or vaccinations are documented, and what does the applicable guidance allow an assessor to infer from them? boundary

Complications and escalation

Record complications and the clinical criteria used to determine urgency.

Escalation-relevant burden

Track ocular, neurological, respiratory, hydration, pain and secondary-infection concerns without automatically attributing each to mpox.

  1. Which complications or functional impairments are observed, suspected or excluded, and how is their relationship to mpox assessed? measurement
  2. Which findings meet the applicable criteria for urgent assessment, specialist consultation or inpatient care, and who must review them? action
Exposure and transmission Represent plausible acquisition events and opportunities for onward transmission.

Acquisition context

Separate reported exposure mechanisms from inferred sources of infection.

Qualified exposure history

Capture relevant human, material and animal contacts with timing and evidential confidence.

  1. What close contact, contaminated-material contact, animal contact or pregnancy-associated exposure is reported, and when? provenance
  2. Is the proposed source confirmed, plausible or unknown, and what evidence would distinguish competing acquisition events? boundary

Onward transmission assessment

Connect episode timing and contact circumstances to prevention decisions.

Contact window and precautions

Record the policy-defined assessment window separately from uncertain infectiousness at a particular moment.

  1. Which dated guidance determines the contact-assessment interval, and how do uncertain onset dates affect its boundaries? boundary
  2. Which household, intimate, healthcare or animal contacts fall within that interval, and what precautions or authorised follow-up require review? action
Care, prevention and resolution Connect the episode assessment to supported interventions and documented closure.

Intervention eligibility

Separate care for illness from prevention after exposure and record the basis for each option.

Care and prevention options

Support review of symptom care, additional therapies and vaccination without embedding permanent eligibility rules.

  1. What symptom burden and complications determine supportive-care needs, and what response has been observed? action
  2. For an exposed person, how do exposure timing, symptoms and vaccination history affect eligibility under current post-exposure guidance? action
  3. If additional therapy is considered, what current evidence, eligibility criteria, local authorisation and clinician decision support it? provenance

Resolution and public-health disposition

Keep clinical recovery, release from precautions and administrative closure separate.

Documented episode disposition

Record healing evidence, residual effects and the authority for closure; WHO describes infectiousness continuing until sores heal and new skin forms. [WHO mpox fact sheet](https://www.who.int/news-room/fact-sheets/detail/mpox)

  1. What skin and mucosal healing evidence supports release under the applicable guidance, and who documented that determination? action
  2. What residual pain, scarring, other sequelae or unresolved symptoms require follow-up after the acute episode? measurement
  3. Which local reporting duties remain, and what minimum necessary information may an authorised actor disclose? action
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.

Reported evidence

Findings from the breadth pass, kept separate from the structural claims.

Kinds and varieties

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

  1. Which of these kinds and varieties hold for the sense of mpox this model covers, and on what evidence? provenance

Identifiers and schemes

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

  1. Which of these identifiers and schemes hold for the sense of mpox this model covers, and on what evidence? provenance

Standards and regulation

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

  1. Which of these standards and regulation hold for the sense of mpox this model covers, and on what evidence? provenance

Real-world use

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

  1. Which of these real-world use hold for the sense of mpox this model covers, and on what evidence? provenance

Typical measurements

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

  1. Which of these typical measurements hold for the sense of mpox this model covers, and on what evidence? provenance

Failure modes and hazards

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

  1. Which of these failure modes and hazards hold for the sense of mpox this model covers, and on what evidence? provenance

Regional variation

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

  1. Which of these regional variation hold for the sense of mpox this model covers, and on what evidence? provenance

Neighbouring kinds and how to tell them apart

Reported by the breadth pass; each item needs checking against its source before it becomes normative.

  1. Which of these neighbouring kinds and how to tell them apart hold for the sense of mpox this model covers, and on what evidence? provenance

Classifiers Filled

Family
Thing Registry
Category
Cross-cutting context
Entry kind
thing
Plane
XCT
Domain
XCT.QLT

What it is Filled

Mpox is a zoonotic orthopoxvirus disease of humans and some other mammals, caused by monkeypox virus (MPXV), an enveloped double-stranded DNA virus in the genus Orthopoxvirus (family Poxviridae), that produces a febrile systemic illness with a characteristic centrifugal vesiculo-pustular rash and is transmitted by close contact, contaminated materials, and, for some clades, sexual networks.

In scope

  • Evidence supporting or contesting an mpox case classification
  • Skin and mucosal manifestations, symptom progression and complications
  • Exposure circumstances and potentially infectious contact intervals
  • Host factors affecting severity and interpretation of illness
  • Mpox-specific requirements for care, prevention and episode closure

Out of scope

  • Monkeypox virus taxonomy, genome organisation and laboratory propagation
  • The patient's complete medical record and unrelated conditions
  • Laboratory assay engineering and specimen-processing procedures
  • Vaccine and medicine manufacture, inventory and general prescribing models
  • Population outbreak dynamics and public-health campaign management

Why it exists Filled

Enable an AI agent to recognise a possible mpox episode, assess its clinical and transmission state, and identify evidence-supported next actions for authorised clinical or public-health review.

Distinguishing features Filled

  • Distinguish the disease mpox from its causative agent, monkeypox virus: a disease episode records illness and case evidence, while a virus record describes the pathogen. [WHO mpox fact sheet](https://www.who.int/news-room/fact-sheets/detail/mpox)
  • For chickenpox, herpes and syphilis lookalikes, require differential assessment and appropriately interpreted testing; rash appearance alone does not establish mpox. [WHO mpox fact sheet](https://www.who.int/news-room/fact-sheets/detail/mpox)
  • Distinguish an MPXV-specific result from a broad non-variola orthopoxvirus result; the latter does not itself identify a clade. [CDC public-health guidance](https://www.cdc.gov/monkeypox/php/public-health-strategy/index.html)
  • Do not exclude mpox because lesions are localised or another sexually transmitted infection is diagnosed; concurrent infections are possible. [CDC clinical overview](https://www.cdc.gov/monkeypox/hcp/clinical-overview/index.html)
  • Distinguish exposure from disease: contact history supports assessment but does not independently establish an mpox episode.

What robots and AI may and may not do Derived, awaiting review

Must not

  • Similar lesions can occur in other conditions, so visual appearance alone cannot establish mpox.

Only with a human decision

  • Mpox is encountered in clinical care, public health surveillance and investigations of contact between infected people, animals and contaminated materials.

May

  • Assemble an evidence-linked mpox case assessment and flag missing diagnostic information
  • Track lesion progression, pain and functional changes to flag clinical reassessment needs
  • Construct a qualified exposure and potentially infectious-contact timeline
  • Identify prevention or treatment options requiring review under current local guidance
  • Prepare the minimum necessary case-reporting and contact-assessment information for authorised handling
  • Evaluate episode closure against documented clinical and public-health criteria

Note: Affordances listed as what may be done; prohibitions collected from the text.

Moral aspects Derived, awaiting review

  • Mpox is encountered in clinical care, public health surveillance and investigations of contact between infected people, animals and contaminated materials.
  • Stigmatising assumptions about affected communities can discourage care seeking and undermine public health work.

Owners Missing, in the backlog

Not described yet. This gap is in the card backlog.

Links to other meta-models Filled

parent

  • Q12353899 - registry parent class
  • Q182672 - registry parent class
  • Q314676 - registry parent class

What else AI and robots need to interact with it Filled

Identity and identifiers required Filled

  • Vercy registry: vr.tr.mpox
  • Wikidata: Q382370 (https://www.wikidata.org/wiki/Q382370)

Direct properties not applicable Not applicable

  • Case classification: Suspected, probable, confirmed, discarded or unresolved, qualified by case-definition authority and version
  • Diagnostic evidence: Linked laboratory report, assay target, specimen site, collection time, result and interpretation
  • MPXV clade attribution: Laboratory-reported clade or subclade with nomenclature version; untyped, pending or indeterminate
  • Episode timing: Dates or bounded intervals for exposure, first symptom, first lesion, sampling and healing; elapsed days
  • Lesion distribution and evolution: Anatomical sites, observed morphology, new lesions, crusting and healing; explicitly unexamined sites
  • Pain and functional impairment: Named pain scale and score; documented effects on swallowing, hydration, urination and defecation
  • Severe-disease modifiers: Linked evidence of immune status, pregnancy, age and relevant skin conditions; known absent or unknown
  • Exposure route and setting: Reported contact mechanism, setting, timing and certainty, including unknown
  • Transmission-precaution status: Awaiting assessment, precautions indicated, precautions active or release documented under a named policy
  • Prevention and treatment history: Linked vaccination, prior mpox, supportive care and other treatment records with dates and provenance

Plane XCT: no invented physical properties.

Recognition optional Filled

  • Lesions can be firm, deep seated and centrally indented, although their appearance varies with disease stage.
  • Lesions may involve genital, anal or oral sites, and a widespread rash is not required.
  • Similar lesions can occur in other conditions, so visual appearance alone cannot establish mpox.

Capabilities and actions required Filled

  • Assemble an evidence-linked mpox case assessment and flag missing diagnostic information
  • Track lesion progression, pain and functional changes to flag clinical reassessment needs
  • Construct a qualified exposure and potentially infectious-contact timeline
  • Identify prevention or treatment options requiring review under current local guidance
  • Prepare the minimum necessary case-reporting and contact-assessment information for authorised handling
  • Evaluate episode closure against documented clinical and public-health criteria

Hazards and failure modes required Filled

  • Failure to recognise an infectious episode can expose close contacts and care workers.
  • Severe disease can cause substantial tissue injury, eye complications or systemic illness.
  • Misclassification based on appearance alone can delay appropriate care for mpox or another condition.
  • Stigmatising assumptions about affected communities can discourage care seeking and undermine public health work.

Standards and interfaces required Filled

  • The International Classification of Diseases, Tenth Revision, issued by the World Health Organization, classifies monkeypox under code B04.

Context of use required Filled

  • Mpox is encountered in clinical care, public health surveillance and investigations of contact between infected people, animals and contaminated materials.
  • Information about the disease supports assessment of suspected illness, transmission prevention and referral for authorised diagnostic review.

Sources Filled

  1. Mpox - WHO disease definition, transmission, clades I/II, case-fatality, vaccination, and PHEIC history
  2. Mpox in the United States and Around the World: Current Situation - Clade Ia/Ib/IIa/IIb epidemiology, 2022 global clade IIb outbreak, and U.S. public-health framing
  3. ICD-11 for Mortality and Morbidity Statistics - 1E71 Mpox - ICD-11 code 1E71 and the 2022 WHO renaming of monkeypox to mpox
  4. Genus: Orthopoxvirus - Monkeypox virus - ICTV species Monkeypox virus (MPXV), family Poxviridae, dsDNA orthopoxvirus taxonomy
  5. Wikidata item Q382370: mpox - identity and sense of the item
  6. Wikipedia: Mpox - general description of the item

Open questions

  • Does vr.tr.mpox own human disease episodes only, or must animal disease be represented here through host-specific extensions?
  • Which case definitions and clinical or public-health authorities should govern classification and actions in each supported jurisdiction?
  • What current evidence resolves the frequency and practical significance of asymptomatic, presymptomatic or post-healing transmission?
  • Which severity assessments and escalation thresholds are sufficiently validated across ages, immune states, clades and care settings?
  • What current evidence establishes treatment benefit, duration of vaccine protection and reinfection risk in the populations this model must support?

Machine files

Provenance

thing registry research (pass 2) · unreviewed

Built from: models/things/publications/thing-q382370/spec.json